N-fragment of edema factor as a candidate antigen for immunization against anthrax.
The nontoxic N-terminal fragment of Bacillus anthracis edema factor (EF) was evaluated as a candidate antigen in an anthrax vaccine using a replication-incompetent adenoviral vector. An E1/E3 deleted adenovirus (Ad/EFn) encoding the N-terminal region 1-254 amino acids of the edema factor (EFn) was constructed using the native DNA sequence of EFn. Intramuscular immunization three times with 10(8) plaque forming units (pfu)/dose of Ad/EFn in A/J mice resulted in 37% and 57% protection against a subcutaneous challenge with B. anthracis Sterne strain spores at a dosage of 200 x LD50 and 100 x LD50, respectively. EF-specific serum IgG responses (including total IgG, IgG1, and IgG2a isotype titers) were robust in the Ad/EFn immunized animals. Interestingly, anti-EF antibodies cross-reacted with anthrax lethal factor (LF), and had a neutralizing capability against both anthrax lethal toxin (Letx) and edema toxin (Edtx), as demonstrated by in vitro toxin neutralization assays using J774A.1 mouse macrophage and Chinese hamster ovary cell (CHO), respectively. Our data suggest that EF plays a role in eliciting protective immunity against anthrax, and that it should be included in a new generation multi-component subunit vaccine.
Zeng
Mingtao
M
Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA. Mingtao.Zeng@urmc.rochester.edu
Xu
Qingfu
Q
Hesek
Eric D
ED
Pichichero
Michael E
ME
D000256:Adenoviridae / Q000235:genetics / Q000276:immunology; D000595:Amino Acid Sequence; D000818:Animals; D000881:Anthrax / Q000276:immunology* / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000032:analysis / Q000096:biosynthesis; D000918:Antibody Specificity; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D001427:Bacterial Toxins / Q000008:administration & dosage / Q000276:immunology*; D003429:Cross Reactions; D000242:Cyclic AMP / Q000378:metabolism; D005260:Female; D007114:Immunization; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis; D051379:Mice; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology*; D013171:Spores, Bacterial / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D022122:Anthrax Vaccines; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D007074:Immunoglobulin G; D010446:Peptide Fragments; D014614:Vaccines, Synthetic; C030325:anthrax toxin; D000242:Cyclic AMP